DeepGlioma uses rapid imaging to analyze tumor specimens taken during an operation and detect genetic mutations more rapidly.
The system identified mutations used by the World Health Organization to define molecular subgroups of the condition with an average accuracy over 90 per cent.
The study was conducted on more than 150 patients with diffuse glioma, the most common and deadly primary brain tumor.
Molecular classification is increasingly central to the diagnosis and treatment of gliomas, as the benefits and risks of surgery vary among brain tumor patients depending on their genetic makeup.
Access to molecular testing for diffuse glioma is limited and not uniformly available at centers that treat patients with brain tumors.
DeepGlioma creates an avenue for accurate and more timely identification that would give providers a better chance to define treatments and predict patient prognosis.